Breaking News

You are here » Indian-Commodity  :  Top News  :  Lasa Supergenerics commences trial production run in Unit IV at Chiplun

27-Nov2017

Lasa Supergenerics commences trial production run in Unit IV at Chiplun

Lasa Supergenerics has commenced the trial production at Unit IV, situated at Chiplun in state of Maharashtra. The Unit IV was earlier known as Unit V. The regular production will be subject to success of the trial runs. The company is geared up to take advantage of this significant opportunity and expand in lines with strategic plans.

The planned production and capacity per annum includes Albendazole Intermediate (400 MT), Fenbendazole Intermediate (200 MT), 2 4 DCP (600 MT), Closantel Intermediate (100 MT) and additionally a few components of backward integration for its recent new launches.

Lasa Supergenerics manufactures and distributes chemicals. The company offers veterinary API products, animal feed ingredients, and reagents for therapeutic uses.



Related News

View all news

Physical rubber prices ruled steady on Saturday

Physical Rubber prices ruled steady on Saturday due to buyer resistance in the market. Spot prices for RSS-4 and RSS-5 variety closed unchanged at Rs 125/ kg and Rs 120.50/ kg respectively.In the futures......

Gold futures trade almost steady on Monday

Gold futures traded almost steady on Monday, with cautious outlook from investors as they eyed on impending report from china showcasing dimmed economic growth to its slowest in 28 years in 2018 in face......

Crude palm oil futures trade in green on rise in demand

Crude palm oil futures traded in green on MCX in line with the firm  trend in Malaysian palm oil prices. Moreover, rise in spot demand from domestic markets coupled with the worries on dip in......

Top News

View all news

Glenmark Pharma recalling 96,240 applicators of its product from US

Glenmark Pharmaceuticals is recalling 96,240 applicators of its product Estradiol vaginal inserts for defective delivery system. The USFDA has termed it as a Class-II recall. The USFDA has classified Class-II......

Infosys hires over 7,600 staff in US

Infosys has hired over 7,600 staff in the US. This hiring is more than three-fourth of its target of recruiting 10,000 American workers. The company is making recruitment from local schools a 'sustained......

SBI to sell 26% stake of SBI payment services

State Bank of India (SBI) is planning to sell 26% stake of its SBI payment services (SPSPL) to Hitachi Payment Services (HPY). After allotment of the shares, SBI shareholding in SPSPL will become 74% from......